SCHEMBL6293558

SCHEMBL6293558

CCOC(=O)C1=C(CC)Nc2n[nH]cc2C1c1ccccc1OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 3/20 0.48
ACHE P22303 3/20 0.47
ALDH1A1 P00352 5/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
KDM4E B2RXH2 3/20 0.44
MAPT P10636 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
LMNA P02545 1/20 0.44
HTT P42858 1/20 0.44
POLB P06746 1/20 0.42
HSP90AA1 P07900 1/20 0.42
TSHR P16473 1/20 0.42
ADORA3 P0DMS8 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CACNA1D Q01668 1/20 0.40
TP53 P04637 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6292394 0.92 DHFR (0.47) DHFRACHEALDH1A1MEN1KMT2A
SCHEMBL6292549 0.90 DHFR (0.45) DHFRACHEALDH1A1MEN1KMT2A
SCHEMBL6296650 0.89 ACHE (0.58) DHFRACHEALDH1A1MEN1KMT2A
SCHEMBL6293581 0.86 TBXA2R (0.49) ALDH1A1MEN1KMT2ACYP2C9CYP2C19
SCHEMBL6293595 0.85 HSD17B10 (0.50) DHFRACHEALDH1A1MEN1KMT2A
SCHEMBL6296647 0.85 GAA (0.49) DHFRACHEALDH1A1MEN1KMT2A
SCHEMBL6292498 0.83 NR3C2 (0.45) ALDH1A1MEN1KMT2AKDM4EMAPT
SCHEMBL6297388 0.83 PKM (0.47) DHFRALDH1A1MEN1KMT2AKDM4E
SCHEMBL6293486 0.82 NR1I2 (0.42) ACHEALDH1A1KMT2ACYP2C9CYP2C19
SCHEMBL6292516 0.82 LMNA (0.49) ALDH1A1MEN1KMT2ACYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6977262-B2 Dihydropyrazolopyridine compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2005-12-20 US disclosed
US-20040052822-A1 Dihydropyrazolopyridine compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-03-18 US disclosed
EP-1355909-A2 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2003-10-29 EP disclosed
WO-2002062795-A9 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2002-10-10 WO disclosed
WO-2002062795-A2 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF MITSUBISHI PHARMA CORPORATION (JP) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040052822-A1 Dihydropyrazolopyridine compounds and pharmaceutical use thereof GSK3B, GSK3A, PYGB DHFR 1211/4885ACHE 63/4885ALDH1A1 944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.